The Post Bayh-Dole Era has seen a dramatic rise in Universities maximizing translational research models to commercialize their innovation. However, translational research models have too often been incremental in nature and the drying up of the financial well may require transformational research models to deliver new cures, better food, and new energy sources. This forum will explore new funding and collaboration models and evaluate this new paradigm’s ability to deliver for universities, companies, patients, and consumers.

Click here to view the complete agenda.

Session ID: 2021

myBIO Chatter

Speakers (11)

contact_9150 Richard Bendis President & CEO Biohealth Innovation
User Karen Bernstein Co-Founder and Chairman BioCentury Publications, Inc
contact_4090 W. Mark Crowell Executive Director, UVa Innovation Associate VP for Research, University of Virginia
contact_4632 Ruxandra Draghia-Akli Director, Health Research European Commission
contact_2019 Edward Lanphier President & CEO Sangamo BioSciences, Inc
User Reid Leonard Senior Director, External Research & Licensing Merck
contact_5034 Diego Miralles Head, Janssen Healthcare Innovation Janssen Pharmceutical Companies of Johnson & Johns
contact_10000 Aaron Miscenich Executive Director New Orleans BioInnovation Center
contact_9973 Daniel Perez, MD Venture Partner Bay City Capital
contact_8480 Rajesh Ranganathan Director, Office of Translational Research National Institutes of Health, NINDS
User Norbert Riedel Chief Scientific Officer Baxter International Inc.

Moderators (2)

User Abigail Barrow, PhD Director Massachusetts Technology Transfer Center
contact_8811 Vicki L. Loise, CMP, CAE Executive Director Association of University Technology Managers